pharmaceutical firms
The Enforcement of Mandatory Disclosure Rules
with P González and N Porteiro, Journal of Public Economics, 2018
Click here for longer summary.
Click here for the latest version of the paper: DahmEtAlEnforcementDisclosure
This paper examines the incentives of firms to invest in information about product risk and to disclose its findings. Continue reading
Implementing Registries and Results Databases of Clinical Trials: Is There a Side Effect?
with P González and N Porteiro, Expert Review of Pharmacoeconomics & Outcomes Research, 2010, DOI
Many parts of the world are currently witnessing a controversial discussion concerning the appropriate design of the environment for clinical trials. Continue reading
Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge
with P González and N Porteiro, Journal of Health Economics, 2009, DOI
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework Continue reading
